This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Protein kinase CK2: a potential therapeutic target for diverse human diseases
Signal Transduction and Targeted Therapy Open Access 17 May 2021
-
Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
Cellular Oncology Open Access 14 October 2020
-
Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
BMC Cancer Open Access 04 March 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G . Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012; 26: 1174–1179.
Trembley JH, Wang G, Unger G, Slaton J, Ahmed K . Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009; 66: 1858–1867.
Martins LR, Lúcio P, Silva MC, Anderes KL, Gameiro P, Silva MG et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724–2731.
Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007; 13: 1019–1028.
Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762–3774.
Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698–1707.
Ruzzene M, Pinna LA . Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2010; 1804: 499–504.
Martins LR, Lúcio P, Silva MC, Gameiro P, Silva MG, Barata JT et al. On CK2 regulation of chronic lymphocytic leukemia cell viability. Mol Cell Biochem 2011; 356: 51–55.
Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010; 70: 10288–10298.
Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther 2012; 11: 994–1005.
Marschke RF, Borad MJ, McFarland RW, Alvarez RH, Lim JK, Padgett CS et al. Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. J Clin Oncol (suppl; abstract 3087) 2011; 29.
Burger JA . Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 96–103.
Choi MY, Kipps TJ . Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 2012; 18: 404–410.
Martins LR, Paulo L, Melao A, Cardoso BA, Stansfield R, Drygin D et al. In vitro and in vivo targeting of chronic lymphocytic leukemia using CX-4945, a clinical-stage CK2-specific inhibitor. ASH Annual Meeting Abstracts 2012; 120: 2897.
Chou T-C . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621–681.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
BJD is a paid consultant for Cylene Pharmaceuticals, who provided CX-4945 for the work described herein. The remaining authors have no conflict of interest.
Rights and permissions
About this article
Cite this article
Prins, R., Burke, R., Tyner, J. et al. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia 27, 2094–2096 (2013). https://doi.org/10.1038/leu.2013.228
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.228
This article is cited by
-
The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target
Oncogene (2022)
-
Protein kinase CK2: a potential therapeutic target for diverse human diseases
Signal Transduction and Targeted Therapy (2021)
-
Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
BMC Cancer (2020)
-
Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
Cellular Oncology (2020)
-
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
BMC Cancer (2019)